{
    "title": "109_hr3950",
    "content": "The \"Responsibility in Drug Advertising Act of 2005\" amends the Federal Food, Drug, and Cosmetic Act to include regulations on direct-to-consumer drug advertising, specifically introducing section 506D. The \"Responsibility in Drug Advertising Act of 2005\" introduces regulations on direct-to-consumer drug advertising, prohibiting such advertising for a drug within the first three years of its approval, with a waiver option available in the third year under certain conditions. The \"Responsibility in Drug Advertising Act of 2005\" regulates direct-to-consumer drug advertising, allowing a waiver for advertising in the third year if it benefits public health. The Secretary can ban advertising if post-approval studies show significant health risks. The \"Responsibility in Drug Advertising Act of 2005\" requires benefit analyses, adverse event reports, and studies to regulate drug advertisements. The Secretary must update regulations within a year of enactment. This section does not limit the Secretary's authority to regulate drug advertising. It applies to drugs approved after a specific date. SEC. 3. PROMINENT DISPLAY OF INFORMATION IN ADVERTISING ON SIDE EFFECTS, CONTRAINDICATIONS, AND EFFECTIVENESS. The amendment to the Federal Food, Drug, and Cosmetic Act requires brief summaries in advertisements regarding side effects, contraindications, and effectiveness to be prominently displayed in terms of font size and location. This amendment applies to any advertisement issued 90 days after the enactment of the Act. The Secretary must revise regulations within 90 days of the Act to implement new advertising requirements. SEC. 4. CIVIL PENALTY. Section 303 of the Federal Food, Drug, and Cosmetic Act is amended to include civil penalties for drug manufacturers, packers, or distributors who violate advertising or promotion regulations. The penalty for the first violation is $250,000, with subsequent violations incurring higher amounts. The Federal Food, Drug, and Cosmetic Act now includes civil penalties for drug manufacturers, packers, or distributors who violate advertising regulations. Penalties for violations can be twice the maximum civil penalty for previous violations. The Secretary may also order distribution of materials in markets where the violative advertisement was distributed. The Federal Food, Drug, and Cosmetic Act now allows for civil penalties for drug manufacturers, packers, or distributors who violate advertising regulations. Violations can result in penalties twice the maximum civil penalty for previous offenses. The Secretary may also order distribution of corrective materials to notify the public and medical community of the violation. Each violation constitutes a separate offense, and penalties are in addition to any other applicable penalties under the law. SEC. 5. ORDER REQUIRING POSTMARKET CHANGE IN LABELING. The Federal Food, Drug, and Cosmetic Act is amended to include a new section 506E for postmarket change in labeling for drugs. SEC. 506E allows the Secretary to order changes in drug labeling for safety. Manufacturers may need to notify the public of these changes. The Secretary of Health and Human Services will conduct a public education campaign to raise awareness about the risks of certain drugs that may outweigh their benefits. Additionally, $2,500,000 is authorized for the FDA in fiscal years 2007 and 2008 to regulate direct-to-consumer drug advertising."
}